(Q34542232)

English

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

scientific article published on September 25, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Martin S. Tallman

11

object named as

Martin S Tallman

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Elisabeth Paietta

5

object named as

Elisabeth Paietta

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Peter H. Wiernik

12

object named as

Peter H Wiernik

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Camille N. Abboud

8

object named as

Camille N Abboud

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jane L. Liesveld

7

object named as

Jane L Liesveld

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Donna Neuberg

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

William Friedenberg

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Gordon Dewald

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Eastern Cooperative Oncology

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jacob M. Rowe

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512295

14 March 2024

John M. Bennett

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512295

14 March 2024

Adel Z. Makary

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512295

14 March 2024

F. Ann Hayes

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512295

14 March 2024

language of work or name

0 references

publication date

25 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

full work available at URL

https://ashpublications.org/blood/article-pdf/103/2/479/1694676/zh800204000479.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512295

14 March 2024

http://ashpublications.org/blood/article-pdf/103/2/479/1694676/zh800204000479.pdf

Portable Document Format

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

479-485

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Adult acute leukemia studies utilizing cytarabine: early Southwest Oncology Group trials

1

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

7

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

9

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia

11

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia

14

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Stem cell factor and stromal cell co-culture prevent apoptosis in a subculture of the megakaryoblastic cell line, UT-7.

18

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Nonparametric Estimation from Incomplete Observations

20

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Treatment of acute myelogenous leukemia in older adults

24

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

25

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

26

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

34

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group

36

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-cont

41

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Concurrent use of growth factors and chemotherapy in acute leukemia

42

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

44

1 reference

10.1182/BLOOD-2003-05-1686

https://api.crossref.org/works/10.1182/BLOOD-2003-05-1686

14 March 2024

Identifiers

10.1182/BLOOD-2003-05-1686

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34542232&oldid=2103801826"